The cellular biology of atherosclerosis with atherosclerotic lesion classification and biomarkers

Leta Melaku1* and Addisu Dabi2

Abstract

Background: Atherosclerosis is a chronic lipid-driven inflammatory disease characterized by a complex endocrine, paracrine, and juxtacrine cross-talk between immune and vascular cells as well as several tissues and organs, including the liver, heart, kidney, adipose tissue, adrenal, pancreatic, and other third party tissues. Atherosclerosis is defined by the accumulation of low-density lipoprotein (LDL) cholesterol and its interaction with immune cells, leading to the formation of atherosclerotic plaques. These plaques are the result of a dysregulated immune response, characterized by the infiltration of monocytes and macrophages into the arterial wall, followed by the formation of a lipid-laden core surrounded by foam cells and inflammatory mediators. The plaque can progress through different stages, from early lesions to advanced plaques, each characterized by specific biological features and clinical outcomes.

Main body: In the classification of atherosclerosis made by the American Heart Association (AHA), AHA Type I lesion is the earliest vascular change described microscopically. AHA Type II lesion is primarily composed of abundant macrophages. AHA Type III lesion is the earliest of progressive lesions, while AHA Type IV lesion consists of an acellular necrotic core. Various biomarkers are implicated in different stages of the pathophysiological mechanism of plaque formation and evolution. C-Reactive Protein (CRP) plays a direct role in promoting the inflammatory component of atherosclerosis. Fibrinogen was demonstrated to be elevated among patients with acute thrombosis. Higher leukocyte count is associated with a greater cardiovascular risk. Cytokines have been implicated in atheroma formation and complications. High rates of protease-activated receptor expression are also induced by interleukin-6 secretion in atherosclerotic lesions and areas of vascular tissue injury. Cluster of differentiation 40 receptor and its ligand have been also detected in atherosclerotic plaques. Osteopontin, acidic phosphoprotein, and osteoprotegerin have emerged as novel markers of atherosclerotic plaque composition. There are also overproductions of matrix metalloproteinases in the rupture-prone regions and promote lipid-necrotic core formation in the atherosclerotic plaque. Myeloperoxidase has been proposed as a marker of plaque instability. Oxidized low-density lipoprotein receptor 1 provides a route of entry for oxidized low-density lipoprotein into the endothelium. A human atherosclerotic lesion also expresses lipoprotein-associated phospholipase A2.

Short conclusion: Atherosclerotic plaques are the battlefield between an unbalanced immune response and lipid accumulation in the intima of arteries. Most of the biomarkers associated with atherosclerosis are indicators of inflammatory response and will also be used for medical purposes.

Keywords: Atherosclerosis, Low-density lipoprotein, Atherosclerotic plaques, Inflammation, Lesion classification, Clinical biomarker and risk prediction
pituatory and sex glands (Badimon et al. 2012; Libby 2012). The first step in the development of atherosclerosis is the exposure of vascular cells to excess lipid with concomitant endothelial activation/dysfunction and the internalization and deposition of lipids in the intima (Badimon and Vilahur 2014). Sites with low or oscillatory endothelial shear stress, located near branch points and along inner curvatures, are the most susceptible (Wentzel et al. 2012). Before development of atherosclerosis, these predilection sites are characterized by changes in endothelial turnover and gene expression (Wentzel et al. 2012), the presence of subendothelial dendritic cells (Millonig et al. 2001) and, in humans, by the presence of adaptive intimal thickening (Schwartz et al. 1995) and with time, the disease spreads to adjacent intima (Velican and Velican 1980). Although the “first event” favoring early lipid deposition within the arterial sub-intimal space has not been identified, the infiltration of low-density lipoproteins (LDL) should be considered as the pivotal step in plaque formation (Hansson 2005). Atherosclerotic plaques are the battlefield among an unbalanced immune response and lipid accumulation in the intima of arteries (Montecucco 2009). Several factors such as smoking, hyperlipidemic states, diabetes, hypertension, physical activity and arterial hypertension are seen to contribute to the genesis of atherosclerosis (Fig. 1) (Novo et al. 1991, 1992) however, any one of these alone is insufficient to produce an atherosclerotic lesion (Singh et al. 2002). With the development of plaque and remodeling of arterial wall, local flow patterns change. This dynamic interplay between flow and the vessel wall may influence the progression of the disease and ultimately the fate of the lesions (Bentzon et al. 2014). The growth of the lesion is abluminal in early stages of the disease, and the progress may vary from total cessation in some cases to very rapid with intervening periods of relative quiescence (Libby et al. 1998). Distinct clinical manifestations are seen depending on the type of vascular bed affected by atherosclerosis because it reduces the perfusion of a tissue.

Powerful laboratory research in the past decade has led to many reviews that describe the biological and genetic bases of atherosclerosis (Lusis 2000; Glass and Witztum 2001; Libby 2003). Despite this progress, the leap from experimental—animal findings to human atherosclerosis and clinical application presents challenges. The laboratory literature and experimental community sometimes assume that the results obtained in cultured cells or animals closely correspond to humans. Although experimental work has helped to unravel some of the principles of atherosclerosis pathophysiology, gaps remain in translation to the clinic, and these breeches require bridging to achieve the full promise of scientific advances in atherosclerosis. This review summarizes the pathophysiology of atherosclerosis plaque progression with emphasis on

**Fig. 1** Schematic design depicting the involvement of oxidized low density lipoprotein (oxLDL), injury of endothelial cells and proliferation of vascular smooth muscle cells (SMC) in the development of atherosclerotic plaque. MAP Mitogen-activated protein
plaque progression. It also offers the recently published literature on different biomarkers and examine whether incorporation of these markers might improve clinical decision.

Atherosclerosis begins with fatty streak which is an accumulation of lipid laden foam cells in the intimal layer of the artery (Alexander and Dzau 2000). Lipid retention is the first step in the pathogenesis of atherosclerosis which is followed by chronic inflammation at susceptible sites in the walls of the major arteries lead to fatty streaks, which then progress to fibroatheromas which are fibrous in nature (Collins et al. 2003; Pedrigi et al. 2014). The location of atherosclerotic lesions varies between men and women. Among women, atherosclerotic lesions are located in the carotid arteries—24.1%; coronary arteries—4.5%; abdominal aorta—22.8% and ilio-lumbar arteries—30.1%. Among men, the incidence of atherosclerosis in the above locations is as follows: 36.9%; 26.1%; 27.2% and 54.1% (Fernández-Friera et al. 2015).

The first classification of atherosclerosis was made by the WHO in 1958 and comprised the following sequence: fatty streak, atheroma, fibrous plaque, and complicated lesions (WHO Study Group on the Classification of Atherosclerotic Lesions and World Health Organization 1958). In the mid-1990s, the American Heart Association (AHA) recommended a new morphological classification based on six lesion types which denote atherosclerosis lesion progression (Stary et al. 1995). Virmani et al. (2000) and van der Wal et al. (1994) further redefined this classification based on the premise that plaque erosion triggers coronary thrombosis.

**Histological classification of atherosclerotic lesions**

Histological classification for atherosclerotic lesions employs a numerical grade based on the characteristics of the plaque (Stary et al. 1995).

**Intimal thickening and fatty streaks**

The term "initial lesion" has also been used for type I. Type I lesions have been described as being most frequent in infants and children. However, such initial lesions can also be found in adults, particularly in those with little atherosclerosis, or in locations of arteries that are lesion resistant (Stary et al. 1994). The initial histological changes in the human intima are minimal. The earliest vascular change described microscopically is intimal thickening (AHA Type I lesion), which consists of layers of smooth muscle cells and extracellular matrix with small, isolated groups of macrophages containing lipid droplets (macrophage foam cells) form (Stary 1987, 1989). Smooth muscle cell proliferation was observed in the media before birth but was rare after birth, whereas the intima replication index was 2–5% (Ikari et al. 1999). Although intimal thickening is more frequent in atherosclerosis prone arteries such as coronary, carotid, abdominal and descending aorta, and iliac arteries (Nakashima et al. 2002), the change is considered adaptive (non-atherosclerotic) since the SMCs exhibit a very low proliferative activity later in life and show anti-apoptotic phenotype (Imanishi et al. 2000; Orekhov et al. 1998).

Type II lesions include fatty streaks, which on gross inspection may be visible as yellow-colored streaks, patches, or spots on the intimal surface of arteries (Stary et al. 1994). The termed “intimal xanthoma” or “fatty streak” (AHA Type II lesion), is a lesion primarily composed of abundant macrophage foam cells interspersed within a smooth muscle cells (SMCs) and proteoglycan rich intima (Fig. 2) (Sakakura et al. 2013).

Microscopically, type II lesions are more distinctly defined than type I lesions. They consist primarily of macrophage foam cells stratified in adjacent layers rather than being present as only isolated groups of a few cells. Intimal smooth muscle cells, in addition to macrophages, now also contain lipid droplets. Type II lesions contain greater numbers of macrophages without lipid droplets than do type I lesions or the normal intima (Stary et al. 1994). T lymphocytes have been identified in type II (Katsuda et al. 1992; Munro et al. 1987), but they are less numerous than macrophages. Although this entity is considered by AHA classification as the earliest lesion of atherosclerosis, this lesion is a reversible process (with little progressive tendencies). Elegant studies of video microscopy have shown that foamy macrophages may leave the wall by passage between endothelial cells into the lumen (Ley et al. 2007). It is clear that lesions in the thoracic aorta, abdominal ventral aorta and mid right coronary lesions may regress with advancing age (15–34 years) (Natural history of aortic and coronary atherosclerotic lesions in youth 1993).

**Pathologic intimal thickening**

The earliest of progressive lesions is the pathologic intimal thickening (PIT, AHA Type III lesion), which is primarily composed of layers of smooth muscle cells in a proteoglycan–collagen matrix that is aggregated near the lumen with an underlying lipid pool consisting of an acellular area, rich in hyaluronan and proteoglycans (mainly versican) with lipid insudation (Virmani et al. 2000). The designation “type III lesion” applies solely to lesions that form the morphological and chemical bridge between type II lesions and atheromas (Stary et al. 1994). The type III lesion is also known as the intermediate lesion, the transitional lesion, and as preatheroma. Its characteristic histological features are microscopically visible extracellular lipid droplets and particles to the extent that pools...
of this material form among the layers of smooth muscle cells of the generally collocalization adaptive intimal thickening (Stary et al. 1994). Another important hallmark of PIT is the variable accumulation of macrophages on the luminal aspect of the plaque (outside the lipid pool) (Fig. 3), although they are not observed in all lesions of PIT (Sakakura et al. 2013). Apoptotic SMCs within lipid pools are recognized by the presence of a thick basement membrane that surrounds the area previously occupied by the smooth muscle cell (cages of the basal lamina) (Sakakura et al. 2013). Type III lesions are found in young adults (Stary et al. 1994).

Atheroma, fibroatheroma and complicated lesions

Atheroma, classified as AHA Type IV lesion, is the first lesion type considered as advanced lesions by histological criteria because there is a lipid core that is well-formed with foam cells and extracellular deposits in the form of cholesterol crystals (Stary et al. 1994). Type V lesions, or fibroatheroma, are characterized by a well-developed lipid core covered by a fibrous capsule (Dos Santos et al. 2021). Fibroatheromas consist of an acellular necrotic core, which is distinguished from lipid pool areas of PIT, as it is made up of cellular debris and is devoid of matrix which is best appreciated by sirius red staining (Fig. 4) (Sakakura et al. 2013). The necrotic core is also covered by a thick fibrous cap consisting of smooth muscle cells in a proteoglycan–collagen matrix (Virmani et al. 2000). For the better understanding of how necrotic cores evolve, fibroatheromas are subclassified into those with “early” and “late” necrotic cores. Lesions of early necrotic core characteristically exhibit proteoglycans, versican, and biglycan and hyaluronan, which are typically absent in late necrotic cores (Sakakura et al. 2013).

Early necrotic core is identified by the presence of foamy macrophage seen infiltration into the luminal surface of the lipid pools. It coincides with the focal presence of calcifying macrophages and the presence of large free cholesterol clefts; there is definite lysis of the extracellular matrix. The late necrotic cores no longer stain for hyaluronan or proteoglycans and on Sirius red stains there is absence of any collagenous matrix. Notably, the majority of macrophages within the areas of necrotic core display features consistent with apoptotic cell death although autophagic processes may also play a role (Bao et al. 2006). The presence of free cholesterol is another discriminating feature of the late necrotic core and is partially attributed to apoptotic cell death of macrophages, in part regulated by acetyl-CoA acetyltransferase 1 (ACAT1) (Tabas 2000). The death of macrophages in the setting of defective phagocytic clearance of apoptotic cells is thought to contribute further to the development of plaque necrosis (Tabas 2000; Tabas et al. 1996). The necrotic core area is surrounded by an overlying layer of thick “fibrous cap” composed mostly of type I and III collagen, proteoglycans and interspersed smooth muscle cells (Sakakura et al. 2013). The fibrous cap is critical for
the maintenance of the integrity of the lesion and is subject to thinning, prior to rupture.

Type VI lesions are known as complicated lesions, because of presence of disorders such as intraplaque hemorrhage, fissures, erosions, or thrombosis (Stary et al. 1995). An update to this classification provided greater detail on complicated lesions, adding type VII atherosclerotic lesions, in which calcification predominates, and type VIII lesions, in which fibrosis predominates (Stary 2000). The progression of lesions does not necessarily occur in a single direction or in a strictly sequential manner (Stary 2000). Atheromas, or advanced type IV lesions, can develop directly to types V, VI, VII, or VIII, without necessarily proceeding through each of those stages (Stary 2000).

**Morphological classification of atherosclerotic lesions**

Other classifications have been proposed in the literature, also based on atherosclerotic lesions in coronary arteries, but considering presence of erosion and plaque rupture and also presence of thrombi (Virmani et al. 2000). The morphology of atherosclerotic plaques plays an important role in clinical presentation. Whereas clinically evident chronic obstructive lesions are generally fibroatheromas, in which the lipid core is small and the fibrous cap is well developed, making the artery more rigid, acute obstructions due to thrombosis more frequently form on plaques with a large lipid core and a thin or inexistent fibrous cap, known as thin-cap fibroatheromas, soft plaques, or vulnerable plaques (Finn et al. 2010). The well-developed lipid core is indicative of predominance of the proinflammatory environment, with large numbers of activated macrophages secreting metalloproteinases that lyse the fibrous cap and make the plaque more predisposed to fissures and ulcerations (Libby et al. 2009). Clinical presentation can vary depending on the degree of lumen obstruction and the velocity with which the obstruction develops (Dos Santos et al. 2021). Chronic obstruction can become clinically evident when the lumen is reduced by at least 70%. However, acute obstructions, associated with thrombosis, can occur with clinically silent plaques (Dos Santos et al. 2021). In the peripheral arteries, a study of patients with peripheral arterial occlusive disease (PAOD) showed that in patients who had undergone an amputation there were advanced atherosclerotic lesions in arterial segments, the majority of which were types V and VI, with degree of obstruction exceeding 75% (Santos et al. 2008). Another study including cases with critical limb ischemia, and analyzing arteries of amputated lower limbs, found a predominance of fibroatheroma lesions and plaques with fibrocalcification.
in the femoropopliteal segment, and an elevated frequency of thrombi and calcification of the tunica media in infrapopliteal arteries (Narula et al. 2018).

A comprehensive morphological classification scheme for atherosclerotic lesions is based on the 7 categories: intimal xanthoma, intimal thickening, pathological intimal thickening, fibrous cap atheroma, thin fibrous cap atheroma, calcified nodule, and fibrocalcific plaque (Virmani et al. 2000). The key features defining these categories are the accretion of lipid in relationship to formation of the fibrous cap, changes over time in the lipid to form a necrotic core, thickening or thinning of the fibrous cap, and thrombosis (Virmani et al. 2000).

**Intimal xanthomata**

“Xanthoma” is a general pathological term that describes focal accumulations of fat-laden macrophages. In humans, most of these intimal xanthomata regress, since the distribution of lesions in the third decade of life and beyond is very different from the fatty streaks seen in children (Velican and Velican 1980). The presence of an intimal xanthoma is not a basis for categorizing lesions in current animal models as “atherosclerotic” (Virmani et al. 2000). This is problematic, based on the fact that the distribution of lesions in animal models is very different from that in the adult human population (Wissler and Vesselinovitch 1968) and the potential for these lesions to regress (Armstrong et al. 1990; Strong et al. 1999).

**Intimal thickening**

While some human lesions may begin as intimal xanthomata, most adult human lesions originate as preexisting intimal masses (Virmani et al. 2000). Evidence for this tenet comes in part from studies by Kim et al. (1987), who showed that atherosclerotic lesions produced in the coronary arteries of hypercholesterolemic swine arise almost exclusively from intimal cell masses. Moreover, the distribution of these normal, developmental intimal masses in children can be correlated with the distribution of characteristic lesions seen in adult humans (Schwartz et al. 1995; Velican and Velican 1980). The origin of fat accumulation subjacent to initially small, very focal, preexisting intimal masses may explain the following paradox. There is very little evidence of cell replication except in early lesions, yet the smooth muscle cells of adult lesion are usually clonal (McCaffrey et al. 1997; Schwartz et al. 1995). Very few replications over a long time could easily account for quite sizeable atherosclerotic lesions.

**Fig. 4** Thrombosis. It is the ultimate complication of atherosclerosis, often complicates a physical disruption of the atherosclerotic plaque. A fracture of the plaque’s fibrous cap, which has enabled blood coagulation components to come into contact with tissue factors in the plaque’s interior, triggering the thrombus that extends into the vessel lumen, where it can impede blood flow.
Thus, the clonality of the lesions may provide a teleological clue, suggesting that the properties of these normal intimal structures may be relevant to the earliest events in the formation of human lesions. Tabas et al., for example, have proposed that the extracellular matrix at these sites may contain enzymes capable of retaining lipids, an initial event in the formation of the necrotic core (Tabas et al. 1993). Unfortunately, there are very few articles on the evolution of early intimal cell masses in humans, and none of these clarify their precise pathological mechanisms of development. Another reason for considering the role of the intima in giving rise to clinically significant lesions comes from the observation that the majority of erosions occur over areas of intimal thickening, with minimal or no evidence of a lipid core (Virmani et al. 2000).

**Fibrous cap atheromata**

The AHA classification distinguishes between lesion types IV and V on the basis of the degree of fibrous cap formation, the extent to which the lipid core becomes rich in cellular debris, and the development of complicating features (Stary et al. 1995). Because there is no clear evidence of a specific sequence of events that relate the extent of changes in the lipid core to the development of a fibrous cap, the use of descriptive terms for plaque classification was suggested. Virmani and his colleagues defined a “fibrous cap” as a distinct layer of connective tissue completely covering the lipid core (Virmani et al. 2000). The fibrous cap consists purely of smooth muscle cells in a collagenous proteoglycan matrix, with varying degrees of infiltration by macrophages and lymphocytes. Thus, a fibrous cap atheroma may have a thick or thin cap overlying a lipid-rich core. The lipid core is also part of our classification. As lesions progress, the core of necrotic debris surrounded by macrophages becomes increasingly consolidated into 1 or more masses comprising large amounts of extracellular lipid, cholesterol crystals, and necrotic debris (Virmani et al. 2000).

**Thin fibrous cap atheromata**

Thin fibrous cap atheroma is a specific plaque type not recognized by the current AHA classification (Stary et al. 1995). Lesions with thin, fibrous caps are those that are most likely to rupture (Burke et al. 1997). The AHA’s discussion suggests this as well; however, their classification scheme also describes type IV lesions as showing fissuring and hemorrhage, including rupture, of the fibrous cap (Stary et al. 1995). Virmani and his colleagues defined a “thin,” fibrous cap as 1 that is < 65 μm thick (Virmani et al. 2000). This definition was derived from a morphometric series of 41 ruptured plaques, in which 95% of the caps measured, <65 μm thick; the mean ± SD plaque thickness was 23 ± 19 μm(Burke et al. 1997). The thin, fibrous cap is distinguished from the earlier fibrous cap lesions by the loss of smooth muscle cells, extracellular matrix, and inflammatory infiltrate. The necrotic core underlying the thin, fibrous cap is usually large; hemorrhage and/or calcification is often present; and intraplaque vasa vasorum are abundant (de Feyter et al. 1995; Fishbein and Siegel 1996).

**Lesions with thrombi**

Rather than creating separate lesion types for rupture and thrombosis, the simplified scheme proposed to classify lesions with thrombi as being affected principally by 3 distinct processes: rupture, erosion, and, less frequently, the calcified nodule. These processes can occur in the setting of a fibrous cap atheroma or, in the case of erosion, pathological intimal thickening (Virmani et al. 2000). A single lesion may contain morphological evidence of both rupture and erosion.

“Plaque rupture” is defined by an area of fibrous cap disruption whereby the overlying thrombus is in continuity with the underlying necrotic core (Virmani et al. 2000). Ruptured lesions typically have a large necrotic core and a disrupted fibrous cap infiltrated by macrophages and lymphocytes. The smooth muscle cell content within the fibrous cap at the rupture site may be quite sparse (Virmani et al. 2000). Risk factors most predictive for this type of lesion are hypercholesterolemia, low serum HDL, and high total cholesterol to HDL cholesterol ratio (Burke et al. 1997). In women > 50 years old, ruptured plaques compose the vast majority of atherosclerotic lesions associated with acute thrombi, and similar to men, there is an association with increased total cholesterol levels (Burke et al. 1998).

“Plaque erosion” is identified when serial sectioning of a thrombosed arterial segment fails to reveal fibrous cap rupture. Typically, the endothelium is absent at the erosion site. The exposed intima consists predominantly of smooth muscle and proteoglycans, and surprisingly, the eroded site contains minimal inflammation (Farb et al. 1996; van der Wal et al. 1994). The term “erosion” was chosen to used, despite its mechanistic implication, because unaware of evidence that such large areas of endothelium are ever absent in nonthrombosed vessels, even over advanced lesions (Davies et al. 1988; Kolodgie et al. 1990; Rosenfeld et al. 1987; Taylor et al. 1989). Erosions constitute approximately 40% of cases of thrombotic sudden coronary death (Farb et al. 1996). Plaque erosions are more common in young women and men <50 years of age and are associated with smoking, especially in premenopausal women (Virmani et al. 2000).
Calcified nodule
A second lesion, albeit an infrequent cause of thrombotic occlusion without rupture, is referred to as a “calcified nodule.” This term refers to a lesion with fibrous cap disruption and thrombi associated with eruptive, dense, calcific nodules. The origin of this lesion is not precisely known, but it appears to be associated with healed plaques. Interestingly, these lesions are found predominantly in the midright coronary artery, where coronary torsion stress is maximal (Virmani et al. 2000). It is unclear whether the fibrous cap wears down from physical forces exerted by the nodules themselves, proteases from the surrounding cellular infiltrate, or both. Thin fibrous cap lesions with eruptive, calcified nodules should not to be confused with fibrocalcific lesions that are not associated with thrombi (Virmani et al. 2000). The latter appear to be the end result of fibrosis and calcification and are often associated with a narrowed lumen. Moreover, this entity does not appear to be a variant of rupture with calcification, since the nodules themselves appear in the lumen in the absence of an overt intimal tear (Virmani et al. 2000).

Fibrocalcific lesions
Some plaques have thick, fibrous caps overlying extensive accumulations of calcium in the intima close to the media (Kragel et al. 1989). Because the lipid-laden necrotic core, if present, is usually small, we refer to this category of lesion as fibrocalcific rather than atheroma. The fibrocalcific lesion is the end stage of a process of atheromatous plaque rupture and/or erosion with healing and calcification (Virmani et al. 2000).

Biomarkers of atherosclerotic plaques formation
Biomarkers are molecules that serve as indicators of biologic and pathogenic processes in living systems (Boamponsem and Boamponsem 2011). Most of the biomarkers associated with atherosclerosis are indicators of inflammatory response. Various biomarkers have been studied as candidates for monitoring the progression of atherosclerotic disease and the majority of them are implicated in different stages of the pathophysiological mechanism of plaque formation and evolution (Fig. 5). As a consequence, the diagnostic/prognostic weight of each one of them leans either towards progression or to the direction of plaque destabilization (Defraigne 2007). In order to detect a vulnerable atherosclerotic plaque that is more likely to cause cardiovascular events, one should focus on studying biomarkers more associated with destabilization rather than disease progression (Triantafllos et al. 2011). Therefore, detection of vulnerable or rupture-prone lesions is of paramount importance so that necessary clinical steps can be taken to prevent the deleterious clinical sequel associated with symptomatic plaque rupture. Specificity and sensitivity vary for each one of these biological markers and they are also different for each vascular bed.

Fig. 5 Inflammatory Biomarkers and their Association with Atherosclerosis. Atherosclerosis is associated with specific inflammatory biomarkers, which can be measured to help evaluate a patient’s risk for heart disease and cardiac events.
Complement reactive protein and pentraxin-3

Complement reactive protein (CRP) is an acute phase protein, primarily synthesized by hepatocytes, and induced by IL-6 with synergistic enhancement of IL-1 or TNF (Volanakis 2001). It was discovered that there was an up regulation of CRP and complement protein levels in plaque tissues (Yasojima et al. 2001). CRP has been proposed to induce a prothrombotic state via induction of tissue factor expression in human monocytes (Paffen et al. 2004). It has been also demonstrated to decrease the expression and bioactivity of endothelial nitric oxide synthase with a subsequent effect on vasodilatation (Venugopal et al. 2002). Subsequently, CRP enhances the release of endothelin (ET-1), adhesion molecules (VCAM-1, ICAM), chemoattractants (MCP-1), migration of SMCs as well as facilitate LDL uptake by macrophage (Verma et al. 2002; Yasojima et al. 2001). Endothelium responds to CRP by intensifying the release of NfKB which initiates the release of cytokines and mediates cell apoptosis (Yasojima et al. 2001). CRP down-regulates both basal and VEGF stimulated angiogenesis, whereas it promotes endothelial apoptosis in a nitrous oxide-dependent fashion (Verma et al. 2004). CRP has been also found to synergistically enhance angiotensin II-induced proinflammatory effects, involving cellular migration and proliferation as well as lesion collagen and elastin content (Wang et al. 2003). These findings support the hypothesis that CRP may play a direct role in promoting the inflammatory component of atherosclerosis and present a potential target for the treatment of atherosclerosis. Unlike many other inflammatory mediators, CRP is not subject to diurnal fluctuation or biological variance, and CRP concentration appears to be proportional to disease severity (Zaninotto et al. 2007). Unfortunately, CRP major limitation is its elevation in systemic inflammation (Zaninotto et al. 2007), which may limit its use as a prognostic marker in postoperative patients.

High sensitivity (hs)-CRP measures accurately levels of CRP to identify low but persistent levels of inflammation. Therefore, high sensitivity (hs)-CRP is vital in predicting atherosclerosis and as such serve as valuable tools in the diagnosis and prognosis of atherosclerosis. According to the European Society of Cardiology guidelines for cardiovascular disease prevention in clinical practice, hs-CRP levels may be measured as part of refined risk assessment only in patients with an unusual or moderate risk profile (class IIb/B recommendation), but not in asymptomatic low-risk or high-risk individuals (class III/B recommendation) (Piepoli et al. 2016), whereas the American College of Cardiology/American Heart Association guidelines state that hs-CRP measurement may be considered if, after quantitative risk assessment, a risk-based treatment decision is uncertain (class IIb/B recommendation) (Goff et al. 2014). A recent large series including more than 1600 patients with asymptomatic carotid atherosclerosis prospectively followed for a median of 11.81 years, found that the risk of all-cause and cardiovascular mortality significantly increased in patients with elevated serum levels of hs-CRP. That risk was level response associated and patients with carotid narrowing of greater than 50% and hs-CRP levels of greater than 0.29 mg/dl had nearly twice as high a risk of cardiovascular mortality compared with patients with carotid stenosis of less than 50% and hs-CRP levels of less than 0.29 mg/dl (Mayer et al. 2016). This association with carotid disease, however, is also controversial. Some studies suggest that high serum hs-CRP levels can predict the presence of carotid plaque (Debing et al. 2008; Schulze Horn et al. 2009; Puz et al. 2013), although other studies could not establish that association (Chapman et al. 2004; Halvorsen et al. 2009) or any correlation with the degree of stenosis (Puz et al. 2013; Eltoft et al. 2017). Plaque type relation to hs-CRP levels is also diverse: some studies report association with echolucent plaques (Rozalski et al. 2013; Yamagami et al. 2004), but other studies correlated hs-CRP levels with increased plaque volume, but not with echolucency (Grenholdt et al. 2001; Halvorsen et al. 2009) or grey-scale median (GSM) value (Andersson et al. 2009a). hs-CRP may predict plaque instability on MR imaging (hypointensity in T1 weighted images)(Shindo et al. 2014) and levels 5 mg/L or greater were significantly associated with a greater number of new cerebral lesions detected on diffusion weighted MR imaging during carotid artery stenting (Pini et al. 2013), but did not correlate with plaque inflammation as determined by carotid artery fluorodeoxyglucose (FDG) uptake on positron emission tomography (PET)(Duivenvoorden et al. 2013; Rudd et al. 2009). A recently reported large series found no significant association between progression of carotid intima-media thickness (cIMT) over a 2-year period and average hsCRP levels; values were also not related in a doseresponse manner, assuming it might be considered as risk marker rather than a causal factor (Wang et al. 2017). Nevertheless, elevated baseline hs-CRP levels were independently associated with increased ischemic stroke risk in a meta-analysis summarizing results of 12 studies, which included more than 2000 patients (Zhou et al. 2016) and also predicted early restenosis after carotid endarterectomy (Tanaskovic et al. 2018).

Pentraxin-3 (PTX3) is another acute phase protein that has been reported associated with the presence of atherosclerotic plaques (Knoflach et al. 2012) and elevated levels of PTX3 were also found in patients with plaque instability undergoing carotid stenting (Shindo et al. 2014). Nevertheless, the association with the presence and severity of carotid stenosis is questioned in other
studies (Bonacina et al. 2013; Norata et al. 2008) and a population-based study involving more than 2400 subjects, showed that PTX3 is not a predictor of incident cardiovascular events (Baragetti et al. 2014).

i. Haematological and neovascularization biomarkers

An alteration of the different subsets of blood cells may reflect a state of activation or prolonged inflammation in a nonspecific fashion. Red blood cell distribution width was found significantly associated with advanced cIMT and with significant carotid artery stenosis (Furer et al. 2015) and white blood cell count with the presence of plaque (Halvorsen et al. 2009; Puz et al. 2013) and with cIMT measure (Willeit et al. 2016).

The white blood cell count in peripheral blood is usually increased in inflammatory and infectious conditions and could also be affected in plaque inflammation (Triantafllos et al. 2011). Higher leukocyte count is associated with a greater cardiovascular risk. In a meta-analysis of seven prospective studies comparing the top with the bottom third of the value distribution, the relative risk of coronary disease was 1.4 (95% CI: 1.3–1.5)(Danesh et al. 1998), rendering leukocytes a valuable marker.

The baseline neutrophil count was also related to a higher prevalence of echolucent plaques (Brevetti et al. 2008) and with the presence of microembolisms by transcranial Doppler examination (Jurk et al. 2010; Yin et al. 2017). Immunity system cells are thought to have a role in atherosclerosis development, as certain T-lymphocyte subtypes and total monocyte count were associated with an increased cIMT (Ammirati et al. 2012; Chapman et al. 2004; Puz et al. 2013). Innate immunity, driven by the monocyte-macrophage complex, may also represent a factor for developing and destabilization of the atheroma plaques (Bernelot Moens et al. 2017), and a significant correlation between plaque neovascularization and circulating levels of CD14+CD16− monocytes (Jaipersad et al. 2014) was also reported. When all data are considered, the relationship between levels of circulating activated monocytes and carotid artery stenosis remains controversial (Sternberg et al. 2013).

The formation of microvessels at the plaque has also been recognized as a contributing factor to destabilization and rupture. Levels of vascular endothelial growth factor (VEGF), were associated with the presence and severity of intracranial (but not extracranial) carotid stenosis (Yu et al. 2017) and inversely correlated with carotid plaque GSM (Heliopoulos et al. 2004; Sayed et al. 2009), predicting a higher presence of intraplaque neovessels as reported in histologic studies.

ii. Fibrinogen and thrombosis-related biomarkers

Fibrinogen is an acute-phase protein produced by the liver. Fibrinogen is a glycoprotein that circulates at a high concentration in blood and it is converted to fibrin to provide strength, flexibility and stability (Triantafllos et al. 2011). It can be used to assess cardiovascular risk in patients with atypical cardiovascular profile (Krobo et al. 1992). Fibrinogen increases plasma viscosity, increases blood coagulation (through increased fibrin and increased aggregation of platelets), increases inflammation (Stec et al. 2000). It has been shown that fibrinogen concentration is higher in people with cardiovascular system diseases compared to healthy people. In addition, it has been found that determining fibrinogen levels in the blood may be useful in assessing the risk of thrombosis. Higher levels of fibrinogen predicted subsequent acute coronary syndromes (ACS) while lower levels, despite elevated cholesterol levels, were associated with lower risk of ACS (Thompson et al. 1995). Elevated fibrinogen levels in patients with peripheral artery disease are associated with increased risk of fatal cardiovascular complications (Doweik et al. 2003). However, it remains unclear whether elevated fibrinogen levels are a cause or consequence of atherosclerosis. In the Copenhagen City Heart Study the relative risk of developing a stroke was almost double in patients with higher fibrinogen levels. Nevertheless they were not associated with echolucent unstable – and therefore vulnerable – carotid plaques (Kofoe et al. 2003).

Unstable carotid artery plaques express a wide array of thrombomodulatory factors. Only plasminogen activator inhibitor-1 (PAI-1) (a fibrinolysis inhibitor) serum levels showed a negative correlation with FDG uptake (the amount of radiotracer uptake) in the carotid artery (Rudd et al. 2009).

iii. Cellular adhesion proteins and endothelial microparticles

Cell adhesion molecules (CAMs) are a subset of cell surface proteins that are involved in the binding of cells with other cells or with the extracellular matrix (ECM), in a process called cell adhesion (Chothia and Jones 1997).

The selectins are a family of heterophilic CAMs that are dependent on fucosylated carbohydrates, e.g.,
Endothelial microparticles (EMPs) are submicron particles (0.1–1.0 mm) released in response to endothelium cell activation or apoptosis promoting oxidative stress and vascular inflammation (Martinez et al. 2020). EMP concentrations were significantly higher in patients with carotid stenosis and in asymptomatic patients with unstable plaques compared with controls (Shiro et al. 2015). Certain specific EMP subsets, were higher in unstable plaques on histologic postoperative analysis in a cohort of patients undergoing endarterectomy (Wekesa et al. 2014).

iv. Cytokines

Many cytokines have been implicated in atheroma formation and complications. The quantities of IL-18 detected in patients with myocardial infarction or unstable angina were greater than in normal patients (Blankenberg et al. 2002). IL-18 has a bearing on the progression and stability of human atherosclerotic plaques (Mallat et al. 2001). Locally, within the atheroma, it also increases the expression of tissue factor, a potent thrombogenic protein (Taubman et al. 1997). Since IL-18 accentuates VCAM-1 and ICAM-1 levels, leukocyte adhesion is also increased as more IL-18 s are synthesized (Szmitko et al. 2003a, b).

Cytokines (IL-1, TNF-α, and IL-6) prompt IL-18 gene expression in macrophages. IL-18 binds to its receptors expressed on lymphocytes (T-helper (Th) 1), ECs, SMCs, and macrophages (Xu et al. 1998) and primes the production of its activators (IL-1β, TNF-α) to establish a positive feedback mechanism that perpetuates inflammation and plaque formation.

Tumor necrosis factor α (TNF-α), also known as cachectin, is a major proinflammatory cytokine involved in atherosclerotic progression from the initial stages of intimal thickening to the subsequent vessel occlusion. It stimulates selectin and adhesion molecule expression and MMP -1–9, -11 and -13 production in the endothelium, VSMCs, and macrophages (Young et al. 2002). TNF-α is associated with a larger plaque size and has an inverse correlation with plaque grey scale median (GSM) estimated by ultrasound examination (Andersson et al. 2009a, 2009b). It is also increased in patients with plaque instability on nonsignificantly (Shindo et al. 2014) and significantly increased in symptomatic patients (Schneiderman et al. 2012).

Interleukin 6 (IL-6) is a master proinflammatory and procoagulant cytokine. IL-6 enhances cell adhesion molecule expression and enhances the production of acute phase reactants such as CRP and TNF-α by the hepatocytes. Studies have confirmed the role of IL-6 as an independent predictor of peripheral artery disease in community screening, irrespective of ethnicity (McDermott et al. 2005; Tzoulaki et al. 2006). Related to coronary artery events, it has also been reported elevated in patients bearing carotid atherosclerotic lesions and associated with cIMT (Chapman et al. 2004), but not with the degree of stenosis (Chapman et al. 2004; Debing et al. 2008; Puz et al. 2013). IL-6 may reflect local
inflammatory activity, because it is upregulated in patients with plaque instability features on MR (Shindo et al. 2014), and increased in patients who underwent carotid endarterectomy (Biscetti et al. 2015) and in the debris retrieved from the cerebral embolic protection devices used during carotid artery stenting (Yang et al. 2016).

II–1β is an important mediator of the inflammatory response involved in cell proliferation, differentiation, and apoptosis. Subcutaneous injection of canakinumab, a human monoclonal antibody that neutralizes II–1β, in patients with well-controlled diabetes mellitus and high cardiovascular risk, significantly decreased systemic inflammation (measured by levels of hsCRP and II–6) without major effect on LDL or HDL (Ridker et al. 2012, 2018), supporting its significance as a mediator of atherosclerosis activity. II–1β was also found independently and significantly associated with the presence of carotid artery stenosis in patients who underwent carotid endarterectomy (Biscetti et al. 2015).

Monocyte chemotactic protein 1 (also known as chemokine C–C motif ligand-2) is one of the key chemokines that regulate migration and infiltration of monocytes and macrophages across vascular endothelium for routine immunological surveillance of tissues, as well as in response to inflammation (Martinez et al. 2020). Monocyte chemotactic protein 1 was found associated with carotid artery stenosis in patients who underwent carotid endarterectomy (Biscetti et al. 2015) and in patients with symptomatic carotid stenosis when compared with asymptomatic carotid stenosis (Grosse et al. 2016).

v. Protease activated receptor

High rates of Protease Activated Receptor (PAR) expression is induced by II–6 secretion in atherosclerotic lesions and areas of vascular tissue injury (Chi et al. 2001; Szmitko, et al. 2003a, b). II–1 and TNF-α in inflamed cells also induce the proinflammatory property of PARs (Hansson 2005). PAR-1 activation in the endothelium facilitates the binding of monocytes when NFκB is stimulated—a process that supports ICAM-1 expression (Dabbagh et al. 1998; Szmitko et al. 2003a, b). PAR-1 and PAR-2 release Weibel Palade bodies which contain P-secretin and von Willebrand factor, molecules that increase the adhesion of leukocytes and platelets to the endothelium (Hamilton et al. 2001; Szmitko et al. 2003a, b). Likewise, with PAR-3 serving as cofactor, PAR-1 activation promotes leukocyte recruitment in atherosclerosis (Szmitko et al. 2003a, b). PAR activity in SMCs has been implicated in the translocation of SMCs from media to the intima and collagen synthesis: critical requirements for the formation of fibrous cap (Szmitko et al. 2003a, b).

vi. Circulating soluble CD40 ligand and urokinase plasminogen activator receptor

CD40 is a protein located on antigen presenting cells. CD40 receptor and its ligand, CD40L (on TH cells), have been detected in atherosclerotic plaques and found to be jointly expressed by activated macrophages, SMCs, vascular endothelial cells and T lymphocytes (Alvaro-González et al. 2002). Membrane-bound CD40L and sCD40L forms interact with the CD40 receptor molecule, leading to the release of matrix MMPs and subsequent destabilization of the plaque (André et al. 2002). Circulating soluble CD40 ligand (sCD40L), largely derived from activated platelets, activates an inflammatory reaction in vascular endothelial cells by the secretion of cytokines and chemokines. Elevated plasma concentrations of sCD40L at baseline predict a subsequent increased risk of future cardiovascular events in apparently healthy women and in angina-stable patients (Triantafillos et al. 2011). Binding of sCD40L to CD40 on SMC and endothelium initiates a cascade of events that lead to endothelial dysfunction and inflammation through facilitation of the production of ROS, proinflammatory cytokines (IL-6, IL-1), VCAM-1, ICAM and MCP-1 (Alvaro-González et al. 2002; Szmitko et al. 2003a, b).

The soluble form of the cell-surface urokinase plasminogen activator receptor is released by endothelial and immune cells by proteolytic cleavage in an inflammatory environment. Plasma soluble urokinase plasminogen activator receptor (suPAR) is predictive of prevalent carotid and peripheral atherosclerosis and of incident events (Sanman Tahhan et al. 2017). Levels were higher in patients with symptomatic carotid stenosis (Edsfeldt et al. 2012) and among symptomatic patients, higher in those with stroke or transient ischemic attack than in those with amaurosis fugax (Olson et al. 2010). These results may indicate that suPAR is a biomarker of the instability and severity of the thrombotic consequences of atheroma.

vii. Vascular calcification markers

Data derived from clinical studies support the notion that increased serum levels of the osteopontin (OPN), an acidic phosphoprotein, and osteoprotegerin (OPG), have emerged as novel markers of atherosclerotic plaque composition, are positively associated with acute cardiovascular events, coronary disease severity and poor long-term cardiovascular outcomes (Kiechl et al. 2004; Kurata
et al. 2006). At present, only one study concerning pharmaceutical interventions with intensive lipid-lowering therapy with statins has demonstrated the attenuation of serum OPN and OPG levels and enhanced carotid plaque echogenicity, and thereafter stability, in patients with carotid stenosis (NPE Kadoglou et al. 2008). Circulating OPG levels were higher in patients bearing carotid stenosis (Davaine et al. 2014) with unstable atherosclerotic plaques (Straface et al. 2011) and in symptomatic vs asymptomatic patients (who showed greater calcification)(Schiro et al. 2015). Patients with echogenic plaques had lower OPG levels in a healthy population report (Vik et al. 2007), but higher in other studies (NPE Kadoglou et al. 2008).

viii. Matrix metalloproteinases
Matrix metalloproteinases (MMPs) are a class of zinc-dependent endopeptidases with proteolytic activity toward one or more components of the extracellular matrix that may be involved in the process of plaque destabilization and cap erosion (Halim and Newby 2009; Kadoglou and Liapis 2004). An imbalance between these enzymes and their inhibitors (tissue inhibitors of metalloproteinases may lead to matrix degradation and plaque destabilization. At the initial stages of atherogenesis, MMPs have been also hypothesized to mediate subintimal inflammatory cell infiltration (Dorweiler et al. 2008). Therefore, degenerative proteases seem to additionally promote lipid-necrotic core formation in the atherosclerotic plaque.

Histopathological studies and experimental models have revealed overproductions of MMPs in the rupture-prone regions of atherosclerotic plaques. Histological analysis of specimens obtained from patients with unstable angina has demonstrated a remarkable increase in intracellular MMP-9 levels than those with stable angina. Studies have confirmed MMP-9 plasma concentrations predicted stroke and cardiovascular death in patients with ≥ 50% carotid stenosis, although not independently (Eldrup et al. 2006; Jefferis et al. 2010). The positive predictive value of MMP-9 was significantly enhanced when combined with other members of the MMP family (MMP-7, MMP-8 and MMP-12 and their tissue inhibitor TIMP-1)(Jiang et al. 2004; NP Kadoglou and Liapis 2004) or with plaque echolucency (NP Kadoglou et al. 2005). Carotid plaques from surgery samples were also analyzed histologically and features of instability were found in patients with higher serum levels of tissue inhibitor of matrix protease 1, MMP-1, and MMP-7 (Pelisek et al. 2009). MMP-7 was also elevated in the sera of patients who had a stroke 2 to 6 months before (Cheng et al. 2009). MMP-9 levels were higher in patients with active carotid plaques at PET imaging (Rudd et al. 2009) and symptomatic patients submitted to carotid endarterectomy showed higher serum levels of MMP-2 and MMP-9 (Alvarez et al. 2004). Additionally, elevated levels of MMP-9 were found in the debris retrieved from the cerebral embolic protection devices used during carotid artery stenting (Yang et al. 2016).

ix. Myeloperoxidase
Myeloperoxidase (MPO) is a hemoprotein produced by polymorphonuclear neutrophils and macrophages and involved in the oxidation of lipids contained within LDL particles, and is thought to promote the formation of foam cells in atherosclerotic plaques (Podrez et al. 1999). Together with MMPs, MPO degrades the collagen layer of atheroma leading to erosion or rupture of plaques and its fatal consequences (Naruko et al. 2002). MPO has been proposed as a marker of plaque instability even if it is not specific to cardiac diseases, as activation of neutrophils and macrophages can occur in infectious, inflammatory or infiltrative disease processes (Triantafillos et al. 2011).

x. Lipid biomarkers
Lipid factors are, together with inflammatory factors, the main actors in the onset, evolution and destabilization of the atheroma plaque, although their role and specific functions remain to be fully understood.

There is compelling evidence on the cardiovascular benefits of LDL cholesterol (LDL-c) lowering, mostly by decreasing the availability of cholesterol particles able to enter the endothelium at the earliest stage of atherosclerosis (Martinez et al. 2020). However, the notion of residual cardiovascular risk recently emerged in patients treated with statins, even after achieving a significant LDL-c reduction, caused by the atherogenic effects of triglyceride-rich lipoproteins (TRLs), particularly the very low-density lipoproteins (VLDL). This finding prompted the use of the concept of non-HDL cholesterol, which reflects cholesterol in all atherogenic particles containing Apo B (LDL-c + VLDL-c + lipoprotein(a) + cholesterol remnants). In this regard, non-HDL cholesterol might outperform LDL-c as a lipid marker of cardiovascular risk, in particular in patients with atherogenic dyslipidemia (Millán et al. 2016). Recently, however, LDL-c, even at normal levels, was found to be independently associated with the presence and extent of early systemic atherosclerosis in the absence
of major cardiovascular risk factors (Fernández-Friera et al. 2017). LDL-c also comprises multiple distinct subfractions, which can be separated by ultracentrifugation, gradient gel electrophoresis or nuclear MR. In contrast to large LDL-c particles, small and dense LDL-c particles have a greater atherogenic potential owing to decreased clearance, greater binding, increased penetrability, and susceptibility to oxidative modification (Martínez et al. 2020). Small and dense LDL-c particles have been associated with coronary heart disease and with carotid atherosclerosis (St-Pierre et al. 2005). Higher plasma levels also independently predicted an increased cIMT and associated proinflammatory activation of peripheral mononuclear cells and endothelial cells in patients with carotid atherosclerosis (Norata et al. 2009).

Oxysterols are oxidized end products of cholesterol metabolism. Their production is enhanced by certain risks factors like tobacco exposure or overuse of frying oil, which produce oxidizing free radicals. Oxysterols are cytotoxic to cells by inducing apoptosis, stimulating the formation of foam cells, and contributing to plaque vulnerability by inducing the upregulation of MMP-9 in macrophages (Vaya 2013). The oxidized LDL cholesterol (ox-LDL-c) plasma levels are inversely correlated with carotid plaque GSM, indicating that lipid peroxidation and reduced antioxidant capacity result in more vulnerable carotid plaques (Andersson et al. 2009a, b; Nishi et al. 2002).

Lectin-like oxidized low-density lipoprotein receptor-1 (LOX-1), expressed in endothelial cells, macrophages and SMCs, recognizes and binds specifically to oxidized low-density lipoprotein (oxLDL), apoptotic cells, activated platelets, advanced glycation end products, and pathogenic organism (Chen et al. 2002). LOX-1 provides a route of entry for oxLDL into endothelium, an action that disrupts normal endothelial function by encouraging monocyte adhesion and infiltration (Boamponsem and Boamponsem 2011). The oxLDL/LOX-1 complex enhances ROS production, death of SMCs and MMP influence on fibrous cap (Li et al. 2003; Szmitko et al. 2003a, b).

High-density lipoprotein cholesterol (HDL-c) protects the vessel wall against plaque progression, inducing the transformation of plaque mass to a higher echogenicity, through the reduction of lipid content and inflammation (Johnsen et al. 2005). Epidemiologic studies have proved the association of HDL-c levels and cIMT (Touboul et al. 2014). Low levels of HDL-c and higher total cholesterol/HDL-c ratios were associated with lower GSM and other characteristics of carotid plaque instability (Mathiesen et al. 2001; Peters et al. 2012). In a similar fashion to low-density lipoprotein cholesterol (LDL-c), HDL-c particle sizes do matter: an HDL size of greater than 8.22 nm was independently associated with low cIMT (Parra et al. 2014) and there was an inverse association between the serum HDL3-cholesterol (HDL3-c) (smaller molecules) and plaque area and a positive association between serum HDL2-cholesterol (HDL2-c)(larger and most effective in cholesterol removal) and plaque thickness (Tiozzo et al. 2014).

Triglyceride-Rich Lipoproteins (TRLs) are a pool of lipoproteins that include chylomicrons, VLDL, intermediate-density lipoproteins (IDL), and other remnant lipid metabolism particles (Martínez et al. 2020). They can predict increased cIMT and are associated with a proinflammatory activation of peripheral mononuclear cells and endothelial cells (Norata et al. 2009). Elevated TRL levels have been identified as an independent risk factor for future ischemic strokes and for echolucent carotid plaques (Kofoed et al. 2002; Nakamura et al. 2009).

Lipoprotein phospholipase A2 (Lp-PLA2) travels along with circulating LDL-c and induces a proinflammatory reaction in the vessel. Its levels are higher at shoulder and necrotic lipid core areas of histology samples (Mannheim et al. 2008). Lipoprotein-associated phospholipase (LpLPA2), expressed by human atherosclerotic lesions, has proinflammatory and proatherogenic functions by generating lysophosphatidylcholine (lysoPC) and non-esterified fatty acid moieties (MacPhee et al. 1999). LysoPC promotes monocyte chemotaxis and increases expression of mononuclear leukocyte adhesion molecules in endothelial cells. LysoPC is suspected to facilitate initiation of atherosclerotic lesion through such activities by binding to peptides and become antigenic and in turn, stimulate T cells (Szmitko et al. 2003a, b). Secretory PLA2 levels, but not Lp-PLA2 levels, have been associated with atherosclerotic plaques and outcome (Lind et al. 2012). Interestingly, however, circulating Lp-PLA2 was found to be increased in patients with high-grade carotid stenosis and unstable plaques in a small series of patients undergoing endarterectomy (Sarlon-Bartoli et al. 2012).

Lipoprotein (a) (Lp(a)) is an LDL-like particle, rich in cholesterol and strongly influenced by genetic background. Elevated levels are associated with an increased risk for cardiovascular diseases (Kassner et al. 2015; Rigamonti et al. 2018), but not carotid
Apolipoproteins (Apos) are the protein components of plasma lipoproteins, which consist of a core of triglyceride and cholesterol esters and a peripheral region of phospholipid, sphingolipid and protein (Martinez et al. 2020). The most relevant subtypes are Apo A-I (the main protein on HDL), Apo B-100 (the main protein on LDL), Apo C-II (important in chylomicrons and VLDL, activates lipoprotein lipase), and Apo E (present in chylomicrons, VLDL, and IDL, allowing the binding of these lipoproteins to the hepatocytes). ApoA-I (or ApoA1) is considered an atheroprotective biomarker for its relation with HDL-c (Martinez et al. 2020). Anti-ApoA-I immunoglobulin G levels were independently associated with cardiovascular disease in the general population and also related to cardiovascular biomarkers in secondary prevention in a recent cross-sectional population study with more than 6000 patients (Antiochos et al. 2016). A meta-analysis including eight cohort and four case–control studies concluded that reduced ApoA-I, increased ApoB levels, and the ApoB/A-I ratio were risk factors for a first ischemic but not hemorrhagic stroke (Dong et al. 2015). This conclusion is supported by a clinical study where ApoA-I levels were lower in ischemic stroke cases vs controls (Walsh et al. 2016). ApoB, which constitutes the gross majority of Apos found in LDL, is considered atheroprotive, as reported in a meta-analysis (Dong et al. 2015), although no significant correlation with major cardiovascular events was found in a large cohort study (van den Berg et al. 2016). The existence of two allele proteins (ApoB100 and ApoB48), might bias these findings, and no report of specific determination of ApoB100 related to carotid atherosclerosis has been published as yet. ApoE presence is high among TRLs such as VLDL and IDL. A large meta-analysis of 22 studies including 30,879 participants demonstrated a significant association between APOE genotype and cIMT (Paternoster et al. 2008) and a positive dose–response association with LDL-c, cIMT, and ischemic stroke was proven in another large meta-analysis (Khan et al. 2013). In contrast, no evidence of an association of circulating ApoE concentration with cardiovascular events was found in a patient cohort including more than 9000 participants, with the authors concluding that these results may be explained by isoform-specific functions (Sofat et al. 2016).

Serum amyloid-A protein (SAA) is an acute phase apolipoprotein related to high-density lipoprotein (HDL). Levels of greater than 10 mg/L were significantly associated with a greater number of new cerebral lesions detected on diffusion weighted MR imaging during carotid artery stenting (Pini et al. 2013) and significantly associated with progressive atherosclerosis measured by ultrasound examination (Schillinger et al. 2005). Higher levels can identify patients with ischemic stroke caused by atherothrombosis vs cardioembolic stroke (Brea et al. 2009).

Adipokine is the term used to name cytokines (cell signaling proteins) secreted by adipocytes. Resistin is involved in glucose and lipid homeostasis. As a marker of an altered metabolic status, levels were significantly higher in symptomatic than in asymptomatic subjects submitted to carotid endarterectomy (Gasbarrino et al. 2016b). Adiponectin is also related to systemic inflammation and metabolic disease, probably by interaction with cHDL efflux capacity (the ability of HDL to accept cholesterol from macrophages, a key step in reverse cholesterol transport)(Marsche et al. 2017). Its relation with cIMT is inconclusive: some studies found a positive correlation (Iglseder et al. 2005; Persson et al. 2015), although a meta-analysis including 55 studies suggested an inconclusive inverse association (Gasbarrino et al. 2016a). In a systematic review of 12 studies, circulating levels of adiponectin predicted a higher risk for ischemic stroke (Gorgui et al. 2017), suggesting an instability-promoting role. Conflicting with these findings, adiponectin levels have been found positively associated with plaque GSM (indicating a more stable, lower fat content plaque) (Gustafsson et al. 2010). Fatty acid binding protein 4 plays an important role in the development of insulin resistance and atherosclerosis in relation to inflammation (Furuhashi et al. 2014). High levels have been found in patients with carotid atherosclerosis, compared with patients having suffered a noncarotid-related stroke (Holm et al. 2011).

Homocysteine is well-documented as a biomarker for cardiovascular diseases. In the carotid setting, high levels were associated with carotid plaque morphology and total carotid plaque area measured by Doppler
ultrasound examination (Alsulaimani et al. 2013) and is also correlated with restenosis after carotid endarterectomy (Alvarez et al. 2012). A recent study including 5393 participants older than 40 years and free of previous cardiovascular events showed that individuals with asymptomatic carotid artery stenosis had higher homocysteine levels (Jia et al. 2016). Very interestingly, in a retrospective analysis of patients submitted to carotid endarterectomy for asymptomatic carotid stenosis, higher homocysteine levels identified a cohort for whom intensive medical therapy alone appeared to be the preferred option (Duschen et al. 2013).

Bilirubin is a potent antioxidant that has been related to cardiovascular disease, cIMT (Hamur et al. 2016), carotid plaque burden (Amor et al. 2017), and hs-CRP levels (Zheng et al. 2016). Lower levels of bilirubin correlated with silent cerebral infarction on cerebral MR, which may precede symptomatic ischemic events (Li et al. 2014).

Small regulatory RNA strands called micro-RNA have been related to atherosclerosis recently in both cellular and animal models. A huge variety of such molecules have been identified, and certain types may work as serum biomarkers of human atherosclerosis and carotid plaque (Dolz et al. 2017; Maitrias et al. 2017), but their potential in stroke prevention requires further investigation (Martinez et al. 2020).

Conclusions
Atherosclerosis is characterized by a complex endocrine, paracrine, and juxtacrine cross-talk between immune and vascular cells as well as several tissues and organs. Several factors are seen to contribute to the genesis of atherosclerosis. The earliest vascular change described microscopically, intimal thickening, consists of layers of smooth muscle cells and extracellular matrix. Most of the biomarkers associated with atherosclerosis are indicators of inflammatory response. There was an up-regulation of CRP and complement protein levels in plaque tissues with elevated fibrinogen and leukocyte count levels are associated with a greater cardiovascular risk. Many cytokines have been also implicated. PAR activation also plays a role in the process of atherosclerosis. The elevated plasma concentrations of sCD40L at baseline as well as the OPN, an acidic phosphoprotein, and OPG are also positively associated with poor long-term cardiovascular outcomes. Together with MMPs, MPO degrades the collagen layer of atheroma leading to erosion or rupture of plaques and its fatal consequences. The oxLDL/LOX-1 complex enhances ROS production, death of SMCs, and MMP influence on fibrous cap. LpPLA₂ also expressed by human atherosclerotic lesions.

Abbreviations
ACAT1: Acetyl-CoA acetyltransferase 1; ACS: Acute coronary syndromes; AHA: American Heart Association; cIMT: Carotid Intima-Media Thickness Test; CD40: Cluster of differentiation 40; CD40L: CD40 ligand; CRP: C reactive protein; ECs: Endothelial cells; ICAM: Intercellular cell adhesion molecule; LDL: Low density lipoprotein; LpPLA₂: Lipoprotein-associated phospholipase A2; LOX-1: Lectin-like oxidized low density lipoprotein receptor-1; MMPs: Matrix metalloproteinases; MPO: Myeloperoxidase; oxLDL: Oxidized low-density lipoprotein; PAR: Protease activated receptor; PI3T: Pathologic intimal thickening; ROS: Reactive oxygen species; sCD40L: Circulating soluble CD40 ligand; SMC: Smooth muscle cell; TNF: Tumor necrosis factor; VCAM-1: Vascular cell adhesion molecule 1; VSMCs: Vascular smooth muscle cells.

Acknowledgements
Authors are grateful to College of Health Sciences Research and Community Office of Arsi University as well as researchers whose documents were used in the preparation of the review.

Authors’ contributions
LM and AD had participated in the design of the study, data analyses, and manuscript preparation, and the authors could have read and approved the final manuscript.

Funding
Nil support in financial or other manner.

Availability of data and material
The datasets used and analyzed during the current study are available from the corresponding author on reasonable request.

Declarations
Ethics approval and consent to participate
Not applicable.

Consent for publication
Not applicable.

Competing interests
The authors declare that there is no conflict of interests regarding the publication of this paper.

Author details
1Department of Biomedical Sciences, College of Health Sciences, Arsi University, Asella, Oromia, Ethiopia. 2Department of Clinical Nursing, College of Health Sciences, Arsi University, Asella, Oromia, Ethiopia.

Received: 23 September 2021 Accepted: 11 December 2021
Published online: 20 December 2021

References
Alexander R, Dzau V (2000) Vascular biology: the past 50 years. Circulation 102: IV-112–IV-116
Alsulaimani S, Gardener H, Elkind M, Cheung K, Sacco R, Rundek T (2013) Elevated homocysteine and carotid plaque area and densitometry in the northern Manhattan study. Stroke 44:457–461
Alvarez B, Ruiz C, Chacon P, Alvarez-Sabin J, Matas M (2004) Serum values of metalloproteinase-2 and metalloproteinase-9 as related to unstable plaque and inflammatory cells in patients with greater than 70% carotid artery stenosis. J Vasc Surg 40:469–475
Alvarez B, Yugeiros X, Fernandez E, Lucchini F, Gene A, Matas M (2012) Relationshp between plasma homocysteine and the morphological and immunohistochemical study of carotid plaques in patients with carotid stenosis over 70%. Ann Vasc Surg 26:500–505
Alvaro-González L, Freijo-Guerrero M, Sádaba-Garay F (2002) Inflammatory mechanisms, arteriosclerosis and ischemic stroke: clinical data and perspectives. Rev Neurol 35:452–462
biomarkers with plaque inflammation assessed by FDG PET/CT: The dal-PLAQE study, JACC Cardiovas Imaging 6:1087–1094
Dusheiko G, Nabi S, Sekij F, Falkensammer, Skirjinska E, Huber W, Wotja J, Waldholt T (2013) Homocysteine improves risk stratification in patients undergoing endarterectomy for asymptomatic internal carotid artery stenosis. Stroke 44:2311–2314
Edsfeldt A, Nitsulescu M, Guffman H, Grönborg C, Persson A, Nilsson M, Persson M, Björkbacka H (2012) Soluble urokinase plasminogen activator receptor is associated with inflammation in the vulnerable human atherosclerotic plaque. Stroke 43:3305–3312
Eldrup N, Gronholt M, Sillehsen H, Nordrengaard B (2006) Elevated matrix metalloproteinase-9 associated with stroke or cardiovascular death in patients with carotid stenosis. Circulation 114:1847–1854
Eltoft A, Amzten K, Hansen J, Wilsgaard T, Mathiesen E, Johnsen S (2017) C-reactive protein in atherosclerosis risk marker but not a causal factor? A 13-year population-based longitudinal study: the Tromsø study. Atherosclerosis 263:293–300
Ezhov M, Sáfáróva M, Afasaniieva O, Pogorelova Q, Tripoten M, Adamanova J, Kononovalov G, Balakhonova T (2015) Specific Lipoprotein(a) atherosclerosis in patients with high Lipoprotein(a) levels. Atheroscler Suppl 18:163–169
Farb A, Burke A, Tang A, Liang T, Manna R, Smialek J, Virmanti R (1996) Coronary plaque erosion without rupture into a lipid core: a frequent cause of coronary thrombosis in sudden coronary death. Circulation 93:1354–1366
Fernández-Friera L, Fuster V, López-Melgar B, Oliva B, García-Ruiz J, Mendiguren J, Bueno H, Pocock S (2017) Normal LDL-cholesterol levels are associated with subclinical atherosclerosis in the absence of risk factors. J Am Coll Cardiol 70:2979–2991
Fernández-Friera L, Peralvo J, Fernández-Ortiz A, Ibañez B, López-Melgar B, Lacuesta M, Oliva B, Mocoroa A, Mendiguren J (2015) Prevalence, Vascular Distribution, and Multiterritorial Extent of Subclinical Atherosclerosis in a Middle-Aged Cohort: The PESA (Progression of Early Subclinical Atherosclerosis) Study. Circulation 131:2104–2113
Finn A, Nakano M, Narula J, Kodolige F, Virmanti R (2010) Concept of vulnerable/unstable plaque. Arterioscler Thromb Vasc Biol 30:1282–1292
Fishbein M, Siegel R (1996) How big are coronary atherosclerotic plaques that rupture? Circulation 94:2662–2666
Furer A, Finkenstein A, Halkin A, Revivo M, Zuzut M, Berliner S, Herz L, Solodukhin A (2015) High red blood cell distribution width and preclinical carotid atherosclerosis. Biomarkers 20:376–381
Furushih M, Saitoh S, Shimamoto K, Miura T (2014) Fatty acid-binding protein 4 (FABP4): pathophysiological insights and potent clinical biomarker of metabolic and cardiovascular diseases. Clin Med Insights Cardiol 8:23–33
Gasbarrino K, Gorgui J, Nauche B, Daskalopoulou S (2016a) Circulating inflammatory markers and angiogenic markers in relation to carotid plaque neovascularization in patients with pre-existing coronary artery disease and carotid stenosis. Ann Med 46:530–538
Jefferis B, Whincup P, Welsh P, Wannamethee G, Rumley A, Lennon L, Thomson A, Lawlor D (2010) Prospective study of matrix metalloproteinase-9 and risk of myocardial infarction and stroke in older men and women. Atherosclerosis 208:557–563
Jia J, Wang A, Wang J, Wu J, Yan X, Zhou Y, Chen S, Zhao X (2016) Homocysteine and its relationship to asymptomatic carotid stenosis in a Chinese community population. Sci Rep 6:37361
Jiang X, Zeng H, Guo Y, Tang B, Li F (2004) The expression of matrix metalloproteinases-9, transforming growth factor-beta1 and transforming growth factor-beta receptor I in human atherosclerotic plaque and their relationship with plaque stability. Chin Med J (engl) 117:1825–1829
Johnsen S, Mathiesen E, Fosse E, Joakimsen O, Stensland-Bugge E, Njølstad I, Arnesen E (2005) Elevated high-density lipoprotein cholesterol levels are protective against plaque progression: a follow-up study of 1952 persons with carotid atherosclerosis in the Tromsø study. Circulation 112:498–504
Jurk K, Ritter M, Schriek C, Van Aken H, Droste D, Ringelstein E, Kehrel B (2010) Activated monocytes capture platelets for heterotypic aggregation in patients with severe carotid artery stenosis. Thromb Haemost 103:1193–1202
Kadouglo N, Daskalopoulou S, Pereira D, Liapis C (2005) Matrix metalloproteinases and diabetic vascular complications. Angiology 56:173–189
Kadouglo N, Gerasimidis T, Golemati S, Kapelouzou A, Karayannacos P, Liapis C (2008) The relationship between serum levels of vascular calcification inhibitors and carotid plaque vulnerability. J Vasc Surg 47:55–62
Gustafsson S, Lind L, Söderberg S, Ingelsson E (2010) Associations of circulating adiponectin with measures of vascular function and morphology. J Clin Endocrinol Metab 95:2927–2934
Halimi S, Newbly N (2009) Prognostic biomarkers in individuals with prevalent coronary heart disease. Dis Markers 26:265–271
Halvorsen D, Johnsen S, Mathiesen E, Njølstad I (2009) The Association between inflammatory markers and carotid atherosclerosis is sex dependent: the Tromsø Study. Cerebrovasc Dis 27:392–397
Hamilton J, Finta A, Cockt, I (2001) Increased expression of protease-activated receptor-2 (PAR2) and PAR4 in human coronary artery by inflammatory stimuli unvels endothelium-dependent relaxations to PAR2 and PAR4 agonists. Circ Res 89:92–98
Hamur H, Duman H, Demirtas L, Bakirci E, Durakoglugil M, Degirmencı H, Kalkan K, Yildirim E (2016) Total bilirubin levels predict subclinical atherosclerosis in patients with prediabetes. Angiology 67:909–915
Hansson G (2005) Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 352:1685–1695
Heliopoulos I, Papazoglou D, Piperidou H, Vadikolias K, Maltezos E, Artemis A, Neurology 69:51–66
Wissler R, Vesselinovitch D (1968) Comparative pathogenetic patterns in atherosclerosis. Adv Lipid Res 6:181–206
Xu D, Chan W, Leung B, Hunter D, Schulz K, Carter R, McInnes I, Robinson J, Liev F (1998) Selective expression and functions of interleukin 18 receptor on T helper (Th) type 1 but not Th2 cells. J Exp Med 188:1485–1492
Yamagami H, Kitagawa K, Nagai Y, Houngaku H, Sakaguchi M, Kuwabara K, Kondo K, Masuyama T (2004) Higher levels of interleukin-6 are associated with lower echogenicity of carotid artery plaques. Stroke 35:677–681
Yang M, Yu Y, Walsh W, Yang J, Baker L, Lennox A, Crowe P, Varcoe R (2016) A microscopic and biomarker evaluation of embolic filter debris collected during carotid artery stenting. J Endovasc Ther 23:275–284
Yasojima K, Schwab C, McGeer E, McGeer P (2001) Generation of C-reactive protein and complement components in atherosclerotic plaques. Am J Pathol 158:1039–1051
Yin R, Ma A, Pan X, Yang S (2017) Biomarkers of cerebral microembolic signals. Clin Chim Acta 475:164–168
Young J, Libby P, Schönbeck U (2002) Cytokines in the pathogenesis of atherosclerosis. Thromb Haemost 88:554–567
Yu F, Lu J, Li Z, Zhou X, Zeng S, Zhan Q, Yuan M, Yang Q (2017) Correlation of plasma vascular endothelial growth factor and endostatin levels with symptomatic intra- and extracranial atherosclerotic stenosis in a Chinese Han population. J Stroke Cerebrovasc Dis 26:1061–1070
Zaninotto M, Mion M, Novello E, Altinier S, Plebani M (2007) New biochemical markers: from bench to bedside. Clin Chim Acta 381:14–20
Zheng J, Wu Y, Li Z, Wang H, Xiao W, Shi Y, Wang T (2016) Low serum total bilirubin concentration was associated with increased high sensitive C reactive protein level in patients with impaired glucose tolerance and type 2 diabetes mellitus subjects. Clin Lab 62:901–907
Zhou Y, Han W, Gong D, Man C, Fan Y (2016) Hs-CRP in stroke: a meta-analysis. Clin Chim Acta 453:21–27

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Submit your manuscript to a SpringerOpen journal and benefit from:

- Convenient online submission
- Rigorous peer review
- Open access: articles freely available online
- High visibility within the field
- Retaining the copyright to your article

Submit your next manuscript at ► springeropen.com